← All trials
NCT04750070
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Apr 30, 2023
- First posted
- Feb 11, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 135
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Center for Diarrheal Disease ResearchLead sponsor
- University of British ColumbiaCollaborator
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
- Muhimbili UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.